Global Leading Market Research Publisher QYResearch announces the release of its latest report “Molecular Imaging Software – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Molecular Imaging Software market, including market size, share, demand, industry development status, and forecasts for the next few years.
Why are radiology departments, pharmaceutical R&D teams, and research institutions investing in molecular imaging software for precision medicine? Traditional medical imaging software faces three limitations: modality-specific silos (PET, SPECT, MRI, and CT software packages operate independently, making cross-modality correlation difficult), qualitative analysis (manual region-of-interest drawing and visual assessment lack quantitative rigor), and limited kinetic modeling (standard software does not support dynamic tracer modeling for pharmacokinetic parameter estimation). Molecular Imaging Software is a computer program system specifically designed for processing, analyzing, and visualizing molecular-level imaging data. Its core function is to visualize the quantitative, dynamic, and spatial distribution of molecular processes in vivo by integrating multimodal imaging data (such as PET, SPECT, MRI, and optical imaging) with biochemical, medical, and computational methods. This software typically includes modules such as image preprocessing (attenuation correction, scatter correction, motion correction), registration and fusion (aligning PET with CT/MRI), feature extraction (SUVmax, SUVmean, metabolic tumor volume), kinetic modeling (Patlak, Logan, two-tissue compartment models), statistical analysis (voxel-wise group comparison), and 3D reconstruction (surface and volume rendering). Its purpose is to provide precise molecular-level information to support early disease diagnosis, drug development, treatment monitoring, and basic research.
The global market for Molecular Imaging Software was estimated to be worth US$ 215 million in 2024 and is forecast to reach a readjusted size of US$ 346 million by 2031, growing at a CAGR of 5.4% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4942546/molecular-imaging-software
Product Definition: What Is Molecular Imaging Software?
Molecular imaging software is a specialized medical imaging and analysis platform designed to extract quantitative information from molecular imaging modalities. The software supports multiple imaging technologies: (a) PET (Positron Emission Tomography) – tracer kinetic modeling, standardized uptake value (SUV) quantification, parametric imaging; (b) SPECT (Single Photon Emission Computed Tomography) – reconstruction, attenuation correction, activity quantification; (c) MRI (Magnetic Resonance Imaging) – molecular MRI contrast agent analysis, spectroscopy; (d) optical imaging – bioluminescence and fluorescence tomography, multispectral unmixing; (e) multimodal fusion – rigid and deformable registration of PET/CT, PET/MRI, SPECT/CT. Key analytical capabilities include: quantitative analysis – SUV (SUVmean, SUVmax, SUVpeak), metabolic tumor volume (MTV), total lesion glycolysis (TLG), standardized uptake value ratios (SUVR), distribution volume ratio (DVR), binding potential (BP). Kinetic modeling – compartmental models (1-tissue, 2-tissue, 3-tissue), reference tissue models (Logan, Patlak, Ichise), graphical analysis. Advanced visualization – 3D volume rendering, fusion overlays, time-activity curves (TACs), parametric maps (Ki, K1, k2, k3, BPnd). The software is used in: (i) clinical diagnostics – oncology (tumor staging, therapy response assessment), neurology (Alzheimer’s disease amyloid/tau PET, Parkinson’s disease dopamine transporter SPECT), cardiology (myocardial perfusion PET, viability assessment); (ii) drug development – PET tracer biodistribution studies, target occupancy quantification, dose-finding trials; (iii) preclinical research – small-animal PET/SPECT/optical imaging, transgenic mouse models, therapeutic efficacy studies.
Market Segmentation: Software Type and Application
By Software Type (Imaging Modality Focus):
-
Nuclear Medicine Molecular Imaging Software – 35–40% of market value. Specialized for PET and SPECT data analysis. Includes reconstruction algorithms (OSEM, MLEM, filtered back projection), scatter and attenuation correction, SUV quantification, and kinetic modeling.
-
Multimodal Fusion Software – 30–35% of market, fastest-growing (7–8% CAGR). Aligns and fuses PET, SPECT, MRI, CT, and optical images. Includes rigid registration (based on fiducial markers or landmarks) and deformable registration (non-linear warping for soft tissue alignment).
-
Optical Molecular Imaging Software – 15–20% of market. For bioluminescence and fluorescence imaging in preclinical research. Includes spectral unmixing, 3D tomography reconstruction, and ROI analysis.
-
Others – 10–15% of market (ultrasound molecular imaging software, photoacoustic imaging software).
By Application (Clinical and Research End-Use):
-
Precision Oncology Diagnosis and Treatment – Largest segment (40–45% of market). Tumor staging, therapy response assessment (PERCIST, RECIST criteria), radionuclide therapy dosimetry (177Lu-PSMA, 90Y microspheres).
-
Neuroscience Research – 20–25% of market. Alzheimer’s disease (amyloid PET, tau PET), Parkinson’s disease (DAT SPECT), epilepsy focus localization, brain tumor imaging.
-
Cardiovascular Disease Assessment – 15–20% of market. Myocardial perfusion PET (absolute myocardial blood flow quantification), cardiac sarcoidosis (FDG PET), atherosclerosis plaque imaging.
-
Drug Development – 10–15% of market, fastest-growing (8–10% CAGR). PET tracer development, target occupancy studies (occupancy of drug candidate at receptor), biodistribution and dosimetry for radiopharmaceuticals.
-
Others – 5–10% of market (infectious disease imaging, inflammation imaging, gene expression imaging).
Key Industry Characteristics Driving Strategic Decisions (2025–2031)
1. The Quantitative Imaging Imperative: From Qualitative to Quantitative
Oncology clinical trials and routine practice are shifting from qualitative visual assessment to quantitative imaging biomarkers. PET response criteria (PERCIST) require SUVpeak measurement and percentage change calculation – not possible with standard viewing software. Alzheimer’s disease diagnosis uses amyloid PET SUVR quantification with cerebellar reference region – requiring automated segmentation and standardized processing. The shift to quantitative imaging drives demand for specialized molecular imaging software with validated quantification workflows. For pharmaceutical companies, quantitative PET imaging is required for FDA and EMA approvals of new oncology and neurology drugs (FDA guidance “Clinical Trial Imaging Endpoint Process Standards” requires quantitative analysis). The market for clinical trial imaging software (including PET, SPECT, and fusion) is growing at 8–10% CAGR, outpacing the overall market.
2. Technical Challenge: Standardization and Reproducibility
The primary technical challenge for molecular imaging software is ensuring standardization and reproducibility across sites, scanners, and processing pipelines. SUV quantification varies with: (a) scanner calibration (cross-calibration factor), (b) reconstruction parameters (iterations, subsets, filter), (c) attenuation correction method (CT-based vs. transmission), (d) ROI placement (manual vs. automated vs. semi-automated), (e) normalization factors (injected dose, patient weight, lean body mass, body surface area). Inter-site variability in SUV can be 15–30% without standardized protocols. Solutions include: (a) digital phantoms – software-based quality control with known activity distributions; (b) automated segmentation – AI-based tumor delineation reducing operator variability; (c) harmonization algorithms – post-processing to reduce scanner-specific bias; (d) cloud-based analysis – centralized processing for multi-center trials. GE HealthCare (October 2025) launched a cloud-based molecular imaging software platform with automated SUV quantification and cross-scanner harmonization, reducing inter-site variability from 20% to 8% in multi-center trials.
3. Industry Segmentation: Clinical vs. Research vs. Drug Development
The molecular imaging software market segments into three distinct tiers.
Clinical Molecular Imaging Software – 50–55% of market value, 4–5% CAGR. Used in hospital radiology and nuclear medicine departments for routine diagnostic imaging. Requirements: regulatory clearance (FDA 510(k), CE Mark), integration with PACS and EHR, workflow efficiency (automated processing), and reimbursement support. Key players: GE HealthCare, Siemens Healthineers, Hermes Medical Solutions.
Preclinical Research Software – 25–30% of market value, 6–7% CAGR. Used in academic and pharmaceutical research laboratories for small-animal imaging. Requirements: support for multiple preclinical scanners (Bruker, MR Solutions, PerkinElmer), advanced kinetic modeling, and batch processing for high-throughput studies. Key players: Bruker, Cytiva, MR Solutions.
Drug Development Software (Clinical Trial Imaging) – 20–25% of market value, 8–10% CAGR – fastest-growing. Used by pharmaceutical CROs and imaging core labs for PET/SPECT endpoint analysis. Requirements: 21 CFR Part 11 compliance (electronic records), blinding and randomization tools, audit trails, and validated quantification workflows. Key players: Hermes Medical Solutions, Convergent Imaging Solutions, Inter Medical.
4. Recent Market Developments (2025–2026)
-
GE HealthCare (October 2025) received FDA 510(k) clearance for its AI-powered PET/CT quantification software with automated tumor segmentation (lung, liver, lymph nodes) and PERCIST response assessment. The software reduces physician reading time by 40%.
-
Siemens Healthineers (November 2025) launched a PET/MRI fusion software with deformable registration for brain imaging, enabling accurate alignment of PET amyloid/tau data with high-resolution MRI for Alzheimer’s disease clinical trials.
-
Hermes Medical Solutions (December 2025) announced a cloud-based platform for multi-center oncology trials, with automated SUV harmonization across 10+ scanner models (GE, Siemens, Philips, Canon) and centralized quality control.
-
FDA (January 2026) published final guidance on “Quantitative Imaging in Clinical Trials,” requiring detailed documentation of image acquisition, reconstruction, and analysis methods – including software version, parameters, and validation data. The guidance increases demand for validated, auditable molecular imaging software.
-
European Society of Molecular Imaging (ESMI) (February 2026) published standardized protocols for PET quantification in oncology trials, recommending specific software tools and analysis workflows – accelerating adoption of standardized software across European clinical sites.
5. Exclusive Observation: AI Integration and Automated Reporting
The integration of artificial intelligence (AI) and deep learning into molecular imaging software is transforming analysis workflows. AI capabilities include: (a) automated organ segmentation – whole-body PET/CT segmentation (lung, liver, bone, lymph nodes) in 30 seconds vs. 10–15 minutes manually; (b) lesion detection and classification – identifying suspicious lesions with >90% sensitivity; (c) treatment response prediction – baseline PET features predicting complete response to immunotherapy; (d) automated reporting – generating structured reports (RECIST, PERCIST, Lugano criteria) with measurements, comparisons, and impressions. Inter Medical (February 2026) launched an AI module that automatically quantifies 50+ lesions across 8 anatomical regions and generates a formatted report in 2 minutes (vs. 20–30 minutes manually). For clinical molecular imaging software, AI integration reduces physician workload and improves consistency – leading to faster adoption in high-volume centers. QYResearch estimates that AI-powered molecular imaging software will represent 40–50% of market value by 2030, up from 15–20% in 2025.
Key Players
Bruker, Carestream, Convergent Imaging Solutions, Cytiva, GE HealthCare, Hermes Medical Solutions, Inter Medical, KODAK, MR Solutions, Siemens Healthineers.
Strategic Takeaways for Radiology Directors, Pharmaceutical R&D Executives, and Investors
-
For radiology and nuclear medicine directors: Replace general-purpose DICOM viewers with specialized molecular imaging software for PET/SPECT quantification. The shift to PERCIST response criteria and quantitative amyloid/tau PET requires automated SUV measurement and kinetic modeling. AI-powered software reduces reading time by 40–50% and improves inter-reader agreement.
-
For pharmaceutical R&D executives (oncology, neurology): For multi-center clinical trials, specify a centralized, cloud-based molecular imaging software platform with automated harmonization across scanner models. The 15–30% inter-site variability in SUV without standardization can obscure treatment effects. Validated, 21 CFR Part 11 compliant software is required for regulatory submissions.
-
For investors: The 5.4% CAGR for the overall market understates growth in the drug development software subsegment (8–10% CAGR) and the AI-powered software subsegment (10–12% CAGR). Target companies with (a) multi-modality (PET, SPECT, MRI, optical) fusion capabilities, (b) automated AI-based segmentation and quantification, (c) 21 CFR Part 11 compliance for clinical trials, (d) cloud-based platform for multi-center harmonization, and (e) regulatory clearances (FDA, CE Mark, PMDA). As precision medicine expands and molecular imaging becomes central to oncology and neurology care, specialized software demand will continue its steady growth.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
